SCN9A (Nav1.7), CALCA (CGRP), and Nociceptive Pain-Migraine Signaling

The conversion of noxious thermal, mechanical, and chemical stimuli into conscious pain perception (nociception) begins in pseudounipolar primary sensory neurons whose cell bodies reside inside the peripheral dorsal root ganglia (DRG) and cranial trigeminal ganglia (TG). Human mendelian genetics and translational neuropharmacology have validated two peripheral molecular nodes that control action potential electrogenesis and neurogenic inflammation in these sensory afferents without engaging central nervous system (CNS) opioid reward or respiratory circuits:

1. Peripheral Nociceptor Voltage-Gated Sodium Channels (NaV1.7 encoded by SCN9A, NaV1.8 encoded by SCN10A, and NaV1.9 encoded by SCN11A): Operating in series along unmyelinated C-fibers and thinly myelinated Aδ-fibers, NaV1.7 acts as a subthreshold threshold amplifier of generator potentials, whereas tetrodotoxin-resistant NaV1.8 carries the majority (>70–85%) of the inward sodium current during the rising phase of the nociceptive action potential.
2. Calcitonin Gene-Related Peptide (α-CGRP, encoded by CALCA on Chr11p15.2): Generated in trigeminal and DRG neurons via classic tissue-specific alternative RNA splicing and released from perivascular C-fiber and Aδ-fiber terminals during migraine attacks to activate the heterodimeric CLR–RAMP1 (Calcitonin Receptor-Like Receptor + Receptor Activity-Modifying Protein 1) G-protein-coupled receptor complex on meningeal blood vessels and second-order trigeminovascular neurons.

Bidirectional human phenotypes—where biallelic loss-of-function mutations in SCN9A cause Congenital Insensitivity to Pain (CIP) while gain-of-function mutations cause Inherited Erythromelalgia (IEM) and Paroxysmal Extreme Pain Disorder (PEPD)—together with the clinical triumph of selective peripheral NaV1.8 inhibitors (suzetrigine / VX-548) and anti-CGRP monoclonal antibodies and gepants, exemplify genetically guided drug discovery.

Bidirectional Mendelian Human Phenotypes of SCN9A (NaV1.7)

Located within the sodium-channel gene cluster on chromosome 2q24.3 (adjacent to SCN1A and SCN2A), SCN9A (180.5 kb, 27 exons) encodes NaV1.7, a 1,977-amino-acid (226-kDa) tetrodotoxin-sensitive (TTX-S, IC50 ≈ 2–25 nM) voltage-gated sodium channel expressed selectively in DRG and trigeminal nociceptors, sympathetic ganglion neurons, and olfactory sensory neuron axon terminals inside the olfactory bulb glomeruli. Biophysical patch-clamp recordings show that NaV1.7 displays slow closed-state inactivation (allowing the channel to remain available during slow ramp depolarizations) and generates a subthreshold ramp current between −70 mV and −40 mV that amplifies small TRPV1/TRPA1/PIEZO2 receptor potentials up to the activation threshold (~−35 to −30 mV) of NaV1.8.

In 2004–2006, three distinct human mendelian disorders mapped to SCN9A, establishing a direct biophysical dose-response curve for human pain perception:

1. Autosomal Recessive Congenital Insensitivity to Pain (CIP, Biallelic Loss of Function): Discovered in Northern Pakistani street performers who walked on burning coals and pierced their skin with blades without experiencing pain (carrying homozygous nonsense mutations such as Ser459X, Ile767X, or Trp897X), complete absence of NaV1.7 abolishes acute thermal, mechanical, inflammatory, and visceral pain across the entire body (causing painless bone fractures, corneal scarring, and tongue/lip self-mutilation) while leaving motor strength, light touch, proprioception, and intelligence completely intact—with anosmia (loss of smell) as the sole non-nociceptive deficit (due to failed synaptic glutamate release from olfactory receptor neurons onto mitral cells).
2. Autosomal Dominant Inherited Erythromelalgia (IEM, Activation Gain of Function): Over 30 missense mutations clustered in the S4–S5 intracellular linkers and S5/S6 pore helices of DI, DII, and DIII (such as Leu858His, Leu858Phe, Ile848Thr, and Phe1449Val) shift the voltage dependence of NaV1.7 activation by −7 to −15 mV in the hyperpolarizing direction, slow deactivation, and increase ramp currents. Consequently, mild warmth (>32°C) triggers spontaneous high-frequency firing of DRG nociceptors and sympathetic fibers, causing burning pain, redness, and warmth in the hands and feet relieved only by ice-water immersion.
3. Autosomal Dominant Paroxysmal Extreme Pain Disorder (PEPD, Fast-Inactivation Gain of Function): Missense mutations located directly inside the **DIII–DIV fast-inactivation hinged lid (IFM/IFMT motif, such as Met1627Lys, Thr1464Ile, and Ile1461Thr)** or its DIV S4–S5 receptor pocket prevent complete fast inactivation (producing a persistent steady-state sodium current). Carriers suffer excruciating paroxysmal rectal, ocular, and submandibular pain attacks accompanied by autonomic flushing and harlequin skin color changes triggered by defecation or perineal stimulation (and responsive to carbamazepine, which stabilizes the inactivated state`).

Why NaV1.7 Small Molecules Struggled vs. Selective NaV1.8 Inhibition by Suzetrigine (VX-548)

Despite overwhelming human genetic validation of SCN9A, first-generation small-molecule NaV1.7 inhibitors (such as aryl sulfonamides PF-05089771 and GDC-0276 targeting the fourth voltage-sensing domain VSD4) showed disappointing clinical efficacy in Phase II human pain trials for two mechanistic reasons:

1. Requirement for >80–90% Target Occupancy and Autonomic Sympathetic Blockade: Because NaV1.7 acts as a threshold amplifier with high functional reserve, human nociceptors require >85–90% pharmacological blockade of NaV1.7 to silence action potentials—a dose range at which systemic NaV1.7 inhibitors also block NaV1.7 in postganglionic sympathetic autonomic neurons, causing orthostatic hypotension.
2. Endogenous Enkephalin (PENK) Transcriptional Upregulation in SCN9A-Null Humans: Transcriptomic profiling of SCN9A-null mice and human CIP sensory neurons revealed that complete congenital absence of NaV1.7 (lowering intracellular Na+) transcriptionally upregulates Preproenkephalin (PENK, encoding endogenous met- and leu-enkephalin opioid peptides) by 5- to 10-fold. Indeed, administering the opioid antagonist naloxone to SCN9A-null human CIP patients partially restores their ability to feel noxious thermal and mechanical pain—a developmental transcriptional adaptation not replicated by acute small-molecule NaV1.7 inhibition in adults.

To bypass these limitations, drug discovery pivoted to SCN10A (NaV1.8 on Chr3p22.2), a tetrodotoxin-resistant (TTX-R) channel (where a serine Ser356 replaces the aromatic Tyr/Phe in the DI P-loop that normally binds TTX) expressed exclusively in peripheral DRG and trigeminal nociceptors and completely absent from the human central nervous system and sympathetic vasomotor ganglia. Because NaV1.8 activates at depolarized potentials (~−30 mV) and recovers rapidly from inactivation even during sustained membrane depolarization (or cold temperatures <15°C, where NaV1.7 inactivates), NaV1.8 carries 75–85% of the inward sodium current during the action potential upstroke and drives repetitive nociceptive firing.

Suzetrigine (VX-548 / Journavx, FDA-approved in January 2025 as the first new class of non-opioid acute pain medication in over two decades) binds with >31,000-fold selectivity over all other human NaV isoforms (NaV1.1–1.7 and cardiac NaV1.5/SCN5A) to a human-specific allosteric pocket (containing the KKGS motif) on the second voltage-sensing domain (VSD2) of NaV1.8. Rather than plugging the open pore or trapping the inactivated state (like lidocaine), suzetrigine acts via a reverse-use-dependent tonic mechanism, stabilizing VSD2 in its resting (closed) state (IC50 ≈ 0.68 nM) to prevent action potential initiation in peripheral pain fibers without any CNS sedation, respiratory depression, or addiction liability.

Textbook Tissue-Specific RNA Splicing of the CALCA Gene

Located on Chr11p15.2, CALCA (5.7 kb, 6 exons) represents one of the earliest and most famous molecular biology examples of tissue-specific alternative splicing coupled with alternative cleavage and polyadenylation, producing two completely distinct peptide hormones from a single primary transcript:

• In Thyroid Parafollicular C-Cells (Exons 1, 2, 3, and 4 → Calcitonin): Splicing joins Exon 3 directly to Exon 4, utilizing the proximal polyadenylation site at the 3′ end of Exon 4 (regulated by the splice factor RBFOX1/2 and TIAR). Proteolytic processing of the resulting prohormone yields the 32-amino-acid peptide hormone Calcitonin, which activates G-protein-coupled CT receptors (CALCR) on osteoclasts to inhibit bone resorption and lower serum Ca2+.
• In Trigeminal and Dorsal Root Ganglion Sensory Neurons (Exons 1, 2, 3, 5, and 6 → α-CGRP): Neuronal splicing regulatory factors (such as Fox-1/Fox-2 and Tra2β) repress the weak 3′ splice acceptor and polyadenylation site of Exon 4, causing the spliceosome to skip Exon 4 entirely and splice Exon 3 to Exons 5 and 6 (utilizing the distal Exon 6 polyadenylation site). Proteolytic cleavage and C-terminal amidation of the Exon 5 product yield the 37-amino-acid neuropeptide α-Calcitonin Gene-Related Peptide (α-CGRP) (while a neighbouring paralogous gene on Chr11p15.2, CALCB, constitutively encodes β-CGRP in enteric neurons, differing from α-CGRP by only 3 of 37 amino acids). Mature α-CGRP features an N-terminal disulfide-bonded ring (Cys2–Cys7, essential for receptor agonism), an amphipathic α-helix (residues 8–18), a β-turn hinge, and a C-terminal Phe37-NH2 amide that docks into the extracellular receptor pocket.

The Trigeminovascular CLR-RAMP1 Heterodimer and Anti-CGRP Therapeutics

During the headache phase of a migraine attack (affecting ~14% of the global population), activation of the trigeminovascular system depolarizes pseudounipolar trigeminal ganglion (TG) unmyelinated C-fibers innervating the dura mater and pial cerebral arteries, releasing α-CGRP into the perivascular space (measurable as an acute surge in external jugular venous blood that normalizes upon sumatriptan 5-HT1B/1D administration).

Secreted α-CGRP binds with sub-nanomolar affinity (Kd ≈ 0.1–0.3 nM) to the canonical CGRP Receptor, an obligate 1:1 heterodimer composed of two transmembrane subunits:

1. Calcitonin Receptor-Like Receptor (CLR, encoded by CALCRL on Chr2q32.1): A 7-transmembrane (7-TM) Class B (secretin-family) G-protein-coupled receptor (GPCR) that remains trapped inside the endoplasmic reticulum and cannot bind any ligand on its own.
2. Receptor Activity-Modifying Protein 1 (RAMP1, encoded on Chr2q37.3): A 148-amino-acid single-pass Type I transmembrane chaperone protein whose extracellular three-helix bundle associates with the N-terminal extracellular domain (ECD) of CLR to traffic the complex to the cell surface and directly form half of the hydrophobic C-terminal binding pocket (via Trp74 and Trp84 on RAMP1) that recognizes Phe37-NH2 of α-CGRP (whereas pairing of CLR with RAMP2 or RAMP3 creates adrenomedullin AM1 and AM2 receptors, and pairing of the Calcitonin receptor CALCR with RAMP1 creates the high-affinity Amylin-1 receptor AMY1).

On meningeal vascular smooth muscle cells, myelinated Aδ trigeminal pain fibers, and trigeminal ganglion satellite glial cells, α-CGRP engagement of CLR–RAMP1 activates Gαs–adenylyl cyclase–cAMP–Protein Kinase A (PKA), opening KATP potassium channels to cause potent meningeal arterial vasodilation while sensitizing Aδ-fiber Nav1.8/P2X3 channels and central trigeminal nucleus caudalis (TNC) transmission.

Because peripheral TG neurons and the dura mater lie outside the blood–brain barrier (BBB), both large-molecule monoclonal antibodies (mAbs, which have <0.1–1% BBB penetration) and small-molecule antagonists (gepants, which wedge into the CLR–RAMP1 extracellular interface around Trp74 of RAMP1) achieve high clinical efficacy in acute and preventive migraine treatment without central vasoconstriction (making them safe in cardiovascular patients where 5-HT1B/1D triptans are contraindicated):

• Receptor-Blocking Monoclonal Antibody (IgG2): Erenumab (Aimovig) binds the canonical extracellular interface formed jointly by CLR and RAMP1 (Kd ≈ 56 pM), competitively blocking α-CGRP binding (though constipation occurs in ~3–5% of patients due to enteric CGRP blockade).
• Ligand-Neutralizing Monoclonal Antibodies (IgG2/IgG4/IgG1): Fremanezumab (Ajovy), Galcanezumab (Emgality), and intravenous Eptinezumab (Vyepti) bind directly to circulating α-CGRP and β-CGRP peptides, preventing docking at both canonical CLR–RAMP1 and AMY1 (CALCR–RAMP1) receptors.
• Small-Molecule Oral and Intranasal Gepants: Ubrogepant (Ubrelvy), Rimegepant (Nurtec ODT), Atogepant (Qulipta), and intranasal Zavegepant (Zavzpret) bind the CLR–RAMP1 ectodomain pocket with picomolar affinity (Ki ≈ 20–70 pM), replacing first-generation telcagepant (which caused hepatotoxicity via reactive metabolite formation) with metabolically clean fluorinated/aza-oxindole scaffolds.

Why do extreme gain-of-function mutations in SCN11A (NaV1.9, Leu811Pro) paradoxically cause congenital insensitivity to pain rather than severe pain?

Unlike NaV1.7 (SCN9A) and NaV1.8 (SCN10A), NaV1.9 (SCN11A) exhibits ultra-slow activation and inactivation kinetics that produce a large persistent window current around the resting membrane potential (−70 to −40 mV). While moderate gain-of-function mutations in SCN11A (Arg225Cys, Ala808Gly) depolarize the resting potential slightly (by 3–5 mV) and cause familial episodic pain, the severe de novo mutation Leu811Pro (located at the cytoplasmic gate of DII S6) prevents channel closure altogether, shifting the resting membrane potential of C-fiber nociceptors from −60 mV to −35 mV. At −35 mV, both NaV1.7 and NaV1.8 become permanently locked in steady-state inactivation (depolarization block), rendering the nociceptor incapable of firing action potentials and causing autosomal dominant Congenital Insensitivity to Pain.

Why did rodents lack sensitivity to human-selective CGRP gepants and VX-548 (suzetrigine) during preclinical drug development?

In RAMP1, human primates carry a bulky Tryptophan at position 74 (Trp74) lining the hydrophobic cleft at the CLR–RAMP1 interface, whereas rats and mice carry a smaller positively charged Lysine (Lys74), which reduces the binding affinity of human-optimized gepants (rimegepant, ubrogepant) by >100- to 1,000-fold. Similarly, in NaV1.8 (SCN10A), suzetrigine (VX-548) binds an extracellular loop of VSD2 that diverges between rodents and primates, rendering suzetrigine ~50- to 170-fold less potent at rat NaV1.8 than at human NaV1.8 (IC50 ≈ 0.68 nM), requiring primary human DRG neurons from organ donors for preclinical validation.

How does CGRP signaling at the AMY1 (CALCR-RAMP1) receptor contribute to migraine beyond the canonical CLR-RAMP1 receptor?

In human trigeminal ganglion C-fibers (which synthesize and release α-CGRP but express little canonical CLR), the Calcitonin receptor (CALCR) heterodimerizes with RAMP1 to form the AMY1 (Amylin-1) receptor. Intriguingly, α-CGRP binds and activates AMY1 (CALCR–RAMP1) with nearly equipotent nanomolar affinity (EC50 ≈ 0.2–0.6 nM) to CLR–RAMP1, creating an autocrine positive-feedback loop on C-fibers that may explain why some patients who do not respond to receptor-specific erenumab (which is ~5,000-fold selective for CLR–RAMP1 over AMY1) respond to ligand-neutralizing antibodies (fremanezumab, galcanezumab) or rimegepant.

1. Cox, J. J., Reimann, F., Nicholas, A. K., et al. (2006). "An SCN9A channelopathy causes congenital inability to experience pain." Nature, 444(7121), 894–898. https://doi.org/10.1038/nature05413
2. Amara, S. G., Jonas, V., Rosenfeld, M. G., Ong, E. S., & Evans, R. M. (1982). "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products." Nature, 298(5871), 240–244. https://doi.org/10.1038/298240a0
3. Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018). "CGRP as the target of new migraine therapies — successful translation from bench to clinic." Nature Reviews Neurology, 14(6), 338–350. https://doi.org/10.1038/s41582-018-0003-1
4. Jones, J., Correll, D. J., Lechner, S. M., et al. (2023). "Selective inhibition of NaV1.8 with VX-548 for acute pain." New England Journal of Medicine, 389(5), 393–405. https://doi.org/10.1056/NEJMoa2209870